Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brief vs Prolonged Eptifibatide Infusion Post-PCI
NCT00111566Phase 4Completed
- Sponsor
- UBC Division of Cardiology
- Start
- Dec 2004
- Primary completion
- Jul 2007
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of eptifibatide in coronary artery disease (CAD) and myocardial infarction (MI) (2 arms), sponsored by UBC Division of Cardiology. Primary endpoint: Ischemic injury defined as troponin I release or CK-MB elevation at 24 hours. Started Dec 2004; status: completed.
02
Drugs
eptifibatide
03
Conditions
coronary artery disease (CAD)myocardial infarction (MI)
Beyond the preview
Go deeper on NCT00111566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111566.